Clinical Trial - Trial ChiCTR2200060886
Access comprehensive clinical trial information for ChiCTR2200060886 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by The Second Affiliated Hospital of Chongqing Medical University and is currently Not yet recruiting. The study focuses on lung cancer.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Chinese Clinical Trial Registry data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Free Database
Powered by Pure Global AI
840K+ Trials
ChiCTR2200060886
Phase 1/2
Not yet recruiting
Trial Details
Chinese Clinical Trial Registry • ChiCTR2200060886
View on Chinese Clinical Trial Registry
Untitled Trial
A phase Ⅰ/Ⅱ study of Almonertinib with Bevacizumab in the first-line treatment of EGFR-mutant non-squamous non-small cell lung cancer patients with brain metastases
Study Focus
Sponsor & Location
The Second Affiliated Hospital of Chongqing Medical University
self-financing
China
Timeline & Enrollment
Phase 1/2
N/A
Jun 30, 2024
ICD-10 Classifications
Carcinoma in situ: Bronchus and lung
Secondary malignant neoplasm of lung
Malignant neoplasm of bronchus and lung
Malignant neoplasm: Bronchus or lung, unspecified
Malignant neoplasm: Overlapping lesion of bronchus and lung
Data Source
Chinese Clinical Trial Registry
ChiCTR2200060886
Non-Device Trial